Literature DB >> 12865820

Double genetic modification of adenovirus fiber with RGD polylysine motifs significantly enhances gene transfer to isolated human pancreatic islets.

Juan L Contreras1, Hongju Wu, Cheryl A Smyth, Christopher P Eckstein, Carlton J Young, Toshiro Seki, Guadalupe Bilbao, David T Curiel, Devin E Eckhoff.   

Abstract

BACKGROUND: New strategies for improving durable functional islet mass will be instrumental in facilitating islet transplantation as a cure for type 1 diabetes mellitus. The ability to transfer immunoregulatory or cytoprotective genes into pancreatic islets may enhance survival. Adenoviral vectors (Ad5) have been used widely to deliver therapeutic genes to different tissues. Limitations associated with the use of Ad5 for gene therapy are related to the reliance of the virus on the presence of its primary receptor, the transient nature of the transgene expression, and the immediate inflammatory and immune response elicited by the infection. Because the arginine-glycine-aspartame (RGD) and polylysine (pK7) motifs have been shown to enhance Ad5 infection through an Ad5 receptor-independent pathway, we hypothesized that they could act additively to improve infectivity and reduce toxicity to isolated human pancreatic islets (IHPI).
METHODS: Hand-picked IHPI were infected with nonmodified Ad5, single-modified Ad5 with RGD (Ad5RGD) or pK7 (ad5pK7), and Ad5RGDpK7. Transfection efficiency was evaluated by green fluorescent protein and luciferase expression. Apoptosis was assessed using a quantitative assay, activation of caspase 3 by a colorimetric assay, nuclear factor (NF)-kappaB nuclear translocation using a promoter-luciferase NF-kappaB responsive construct, regulated on activation normal T-cell expressed and secreted (RANTES) by enzyme-linked immunosorbent assay. In vivo functionality was evaluated after transplantation into diabetic nonobese diabetic severe combined immunodeficiency mice.
RESULTS: Compared with unmodified and singly-modified Ad5 vectors, Ad5RGDpK7 demonstrated the highest infectivity. After the infection of IHPI with adenoviral vectors using the minimal dose required to infect greater than 80% of the islet cells (Ad5, 500 viral particles [VP]/cell; Ad5RGD and Ad5pK7, 10 VP/cell; Ad5RGDpK7, 0.1 VP/cell), islets infected with Ad5RGDpK7 presented a significant reduction in apoptosis, NF-kappaB nuclear translocation, RANTES expression, and higher glucose disposal rate; reduced Ad5-driven specific Th1 and antibody response were also observed.
CONCLUSIONS: Ad5RGDpK7 exhibited higher transfection efficiency, allowing a significant reduction in the viral dose required to infect greater than 80% of the islet cells. The reduction in the viral dose was associated with reduced toxicity, inflammation, and immune responses related to Ad5 infection. This strategy may thus be used to successfully modify isolated pancreatic islets.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865820     DOI: 10.1097/01.TP.0000066361.02042.CA

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Efficient Gene Transduction of Dispersed Islet Cells in Culture Using Fiber-Modified Adenoviral Vectors.

Authors:  Hiroyuki Hanayama; Kazuo Ohashi; Rie Utoh; Hirofumi Shimizu; Kazuya Ise; Fuminori Sakurai; Hiroyuki Mizuguchi; Hiroyuki Tsuchiya; Teruo Okano; Mitsukazu Gotoh
Journal:  Cell Med       Date:  2015-08-26

Review 2.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

3.  Strategies to enhance transductional efficiency of adenoviral-based gene transfer to primary human fibroblasts and keratinocytes as a platform in dermal wounds.

Authors:  Alexander Stoff; Angel A Rivera; N S Banerjee; J Michael Mathis; Antonio Espinosa-de-los-Monteros; Long P Le; Jorge I De la Torre; Luis O Vasconez; Thomas R Broker; Dirk F Richter; Mariam A Stoff-Khalili; David T Curiel
Journal:  Wound Repair Regen       Date:  2006 Sep-Oct       Impact factor: 3.617

4.  RGD peptide-modified adenovirus expressing hepatocyte growth factor and X-linked inhibitor of apoptosis improves islet transplantation.

Authors:  Hao Wu; A-Rum Yoon; Feng Li; Chae-Ok Yun; Ram I Mahato
Journal:  J Gene Med       Date:  2011-12       Impact factor: 4.565

Review 5.  Current developments in adenovirus-based cancer gene therapy.

Authors:  Daniel T Rein; M Breidenbach; David T Curiel
Journal:  Future Oncol       Date:  2006-02       Impact factor: 3.404

6.  Adenovirus platform enhances transduction efficiency of human mesenchymal stem cells: An opportunity for cellular carriers of targeted TRAIL-based TR3 biologics in ovarian cancer.

Authors:  Lindsay M Kuroki; Xingjian Jin; Igor P Dmitriev; Elena A Kashentseva; Matthew A Powell; David G Mutch; Allan B Dietz; David T Curiel; William G Hawkins; Dirk Spitzer
Journal:  PLoS One       Date:  2017-12-21       Impact factor: 3.240

7.  A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.

Authors:  Julius W Kim; Jason Miska; Jacob S Young; Aida Rashidi; J Robert Kane; Wojciech K Panek; Deepak Kanojia; Yu Han; Irina V Balyasnikova; Maciej S Lesniak
Journal:  Mol Ther Oncolytics       Date:  2017-05-06       Impact factor: 7.200

8.  Gene transfer of active Akt1 by an infectivity-enhanced adenovirus impacts β-cell survival and proliferation differentially in vitro and in vivo.

Authors:  Robert N Bone; Mert Icyuz; Yanqing Zhang; Yuan Zhang; Wanxing Cui; Hongjun Wang; Ji-Bin Peng; Qiana L Matthews; Gene P Siegal; Hongju Wu
Journal:  Islets       Date:  2012-11-01       Impact factor: 2.694

9.  Genetically modified adenoviral vector with the protein transduction domain of Tat improves gene transfer to CAR-deficient cells.

Authors:  Shihai Liu; Qinwen Mao; Weifeng Zhang; Xiaojing Zheng; Ye Bian; Dongyang Wang; Huijin Li; Lihong Chai; Junli Zhao; Haibin Xia
Journal:  Biosci Rep       Date:  2009-04       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.